|
Medical
Advisories
MASAC RECOMMENDATIONS
AND MEDICAL ADVISORIES
Updated 2/7/06
These Recommendations by MASAC were approved in the Fall
of 2006. For further information and a complete detailed description
of each document, visit
www.hemophilia.org.
MASAC Document
#177
MASAC Recommendations Concerning The Treatment
Of Hemophilia And Other Bleeding Disorders (Revised October
2006)
MASAC Document
#176
MASAC Recommendations Regarding Radionuclide
Synovectomy
MASAC Document
#175
Guidelines For Emergency Department Management
Of Individuals With Hemophilia
MASAC Document
#174
MASAC Recommendations Regarding Rare Coagulation
Factor Disorders
MASAC Document
#173
MASAC Resolution Regarding the Treatment of von
Willebrand Disease
MASAC Document
#172
Recommendations Regarding Women with Inherited
Bleeding Disorders
MASAC Document
#171
MASAC Resolution on National Hemophilia
Foundation Sponsorship of Gene Therapy and Novel
Technologies Workshops
Medical Advisory
#406:
FDA Confirms Low Risk for Creutzfeldt-Jakob Disease
On Monday, November 27th, the Food and Drug Administration
(FDA) released documents relating to the Agency’s assessment
of the risk of acquiring variant Creutzfeld-Jakob Disease
(vCJD), a human form of mad cow disease, for persons with
bleeding disorders who have used US licensed plasma-derived
factor VIII products (pdFVIII). Although there are still too
many uncertainties to allow the Agency to make a precise calculation
of theoretical risk without further study of this issue, FDA
officials and other experts continue to believe that this
risk is exceedingly low but possibly not zero. It is important
to note that there have been no known cases of vCJD in users
of pdFVIII products worldwide, including in the United Kingdom
where the prevalence of vCJD in the general population is
the highest in the world.
On December 15, the agency will convene a panel of consumers,
medical professionals and other experts to advise them on
how best to broadly communicate this information to the public.
NHF will participate on the panel, and will continue to work
closely with the FDA and other government agencies to ensure
that the community receives complete, accurate and timely
information on this subject.
PHYSICIANS: Please distribute this information to
all providers in your area who treat patients with hemophilia.
The CDC will convene a call for HTC Directors on Friday –
more information to follow.
CHAPTERS: Please distribute this information to your
membership.
Please sign up for the Patient Notification System (PNS)
to be notified directly about the latest recall or withdrawal
of recombinant and plasma products. The System is confidential
and time sensitive. It is administered by an independent third-party
organization and is free of charge.
To enroll in the PNS, please go online at http://www.patientnotificationsystem.org/
This material is provided for your general information only.
NHF does not give medical advice or engage in the practice
of medicine. NHF under no circumstances recommends treatment
for specific individuals and in all cases recommend that you
consult your physician or local hemophilia treatment center
before pursuing any course of treatment.
The information
provided on this website in no way replaces the information
and advice provided by a health care professional. A doctor,
nurse or Hemophilia Treatment Center should be contacted regarding
the diagnosis and treatment of any medical condition.
Links
are provided to outside web sites. These sites are not developed
or maintained by FCS Pharmacy. The links are provided for
your convenience only and FCS Pharmacy neither endorses nor
supports the statements they contain in any way. FCS Pharmacy
does not verify the authenticity of these links or the content
they provide.
|
